Change in number of shares and votes in Episurf Medical and formal adjustment of resolution to issue new shares in advance of general meeting

Episurf Medical AB (NASDAQ: EPIS B) has on behalf of shareholders in Episurf Medical AB, conversions of class A-shares to B-shares were carried out during April in accordance with the Articles of Association. Through the conversions, the number of A-shares has decreased by 15,200, and the number of B-shares has increased by the same amount.

The total number of shares amounts to 35,113,686, of which 492,877 are A-shares and 34,620,809 are B-shares. The total number of votes after the conversions amounts to 36,099,440.

As a consequence of the conversion, the board of directors has resolved on a formal adjustment of the resolution to issue in total no more than 70,227,372 new shares which was adopted by the board of directors on 5 April 2019 and which is proposed to be approved by the general meeting on 7 May 2019. The adjusted resolution entails that the maximum number of A-shares that may be issued is adjusted to 985,754 and the maximum number of B-shares is adjusted to 69,241,618, and that further adjustments may be made in the event that additional conversions are carried out before the record date. The adjusted resolution is available at the company's website:

For more  information, please contact:

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website:
This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, trough the agency of the contact person set out above, at 11:00 CEST on April 30, 2019.